Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Disease progression in mice exposed to low-doses of aerosolized clinical isolates of Burkholderia pseudomallei.

Trevino SR, Klimko CP, Reed MC, Aponte-Cuadrado MJ, Hunter M, Shoe JL, Meyer JR, Dankmeyer JL, Biryukov SS, Quirk AV, Fritts KA, Kern SJ, Fetterer DP, Kohler LJ, Toothman RG, Bozue JA, Schellhase CW, Kreiselmeier N, Daye SP, Welkos SL, Soffler C, Worsham PL, Waag DM, Amemiya K, Cote CK.

PLoS One. 2018 Nov 30;13(11):e0208277. doi: 10.1371/journal.pone.0208277. eCollection 2018.

2.

Characterization of in vitro phenotypes of Burkholderia pseudomallei and Burkholderia mallei strains potentially associated with persistent infection in mice.

Bernhards RC, Cote CK, Amemiya K, Waag DM, Klimko CP, Worsham PL, Welkos SL.

Arch Microbiol. 2017 Mar;199(2):277-301. doi: 10.1007/s00203-016-1303-8. Epub 2016 Oct 13.

3.

Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.

Moustafa DA, Scarff JM, Garcia PP, Cassidy SK, DiGiandomenico A, Waag DM, Inzana TJ, Goldberg JB.

PLoS One. 2015 Jul 6;10(7):e0132032. doi: 10.1371/journal.pone.0132032. eCollection 2015.

4.

Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays.

Welkos SL, Klimko CP, Kern SJ, Bearss JJ, Bozue JA, Bernhards RC, Trevino SR, Waag DM, Amemiya K, Worsham PL, Cote CK.

PLoS One. 2015 Apr 24;10(4):e0124667. doi: 10.1371/journal.pone.0124667. eCollection 2015.

5.

Efficacy of postexposure therapy against glanders in mice.

Waag DM.

Antimicrob Agents Chemother. 2015 Apr;59(4):2236-41. doi: 10.1128/AAC.04801-14. Epub 2015 Feb 2.

6.

Characterization of cellular immune response and innate immune signaling in human and nonhuman primate primary mononuclear cells exposed to Burkholderia mallei.

Alam S, Amemiya K, Bernhards RC, Ulrich RG, Waag DM, Saikh KU.

Microb Pathog. 2015 Jan;78:20-8. doi: 10.1016/j.micpath.2014.11.009. Epub 2014 Nov 20.

PMID:
25450887
7.

Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B.

Fritz DL, England MJ, Miller L, Waag DM.

Comp Med. 2014 Oct;64(5):341-50.

8.

Structure-Based Design and Synthesis of a Small Molecule that Exhibits Anti-inflammatory Activity by Inhibition of MyD88-mediated Signaling to Bacterial Toxin Exposure.

Alam S, Javor S, Degardin M, Ajami D, Rebek M, Kissner TL, Waag DM, Rebek J Jr, Saikh KU.

Chem Biol Drug Des. 2015 Aug;86(2):200-9. doi: 10.1111/cbdd.12477. Epub 2014 Dec 8.

PMID:
25393063
9.

Distinct human antibody response to the biological warfare agent Burkholderia mallei.

Varga JJ, Vigil A, DeShazer D, Waag DM, Felgner P, Goldberg JB.

Virulence. 2012 Oct 1;3(6):510-4. doi: 10.4161/viru.22056. Epub 2012 Oct 1.

10.

Humoral immune responses in a human case of glanders.

Waag DM, England MJ, DeShazer D.

Clin Vaccine Immunol. 2012 May;19(5):814-6. doi: 10.1128/CVI.05567-11. Epub 2012 Mar 7.

11.

Burkholderia mallei tssM encodes a putative deubiquitinase that is secreted and expressed inside infected RAW 264.7 murine macrophages.

Shanks J, Burtnick MN, Brett PJ, Waag DM, Spurgers KB, Ribot WJ, Schell MA, Panchal RG, Gherardini FC, Wilkinson KD, Deshazer D.

Infect Immun. 2009 Apr;77(4):1636-48. doi: 10.1128/IAI.01339-08. Epub 2009 Jan 21.

12.

Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.

Waag DM, England MJ, Bolt CR, Williams JC.

Clin Vaccine Immunol. 2008 Oct;15(10):1505-12. doi: 10.1128/CVI.00119-08. Epub 2008 Aug 13.

13.

Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies.

Parthasarathy N, Saksena R, Kováč P, Deshazer D, Peacock SJ, Wuthiekanun V, Heine HS, Friedlander AM, Cote CK, Welkos SL, Adamovicz JJ, Bavari S, Waag DM.

Carbohydr Res. 2008 Nov 3;343(16):2783-8. doi: 10.1016/j.carres.2008.05.021. Epub 2008 Jun 14.

PMID:
18558401
14.

Detection of the host immune response to Burkholderia mallei heat-shock proteins GroEL and DnaK in a glanders patient and infected mice.

Amemiya K, Meyers JL, Deshazer D, Riggins RN, Halasohoris S, England M, Ribot W, Norris SL, Waag DM.

Diagn Microbiol Infect Dis. 2007 Oct;59(2):137-47.

PMID:
17908615
15.

Coxiella burnetii: host and bacterial responses to infection.

Waag DM.

Vaccine. 2007 Oct 16;25(42):7288-95. Epub 2007 Aug 20. Review.

PMID:
17825460
16.

The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model.

Fernandes PJ, Guo Q, Waag DM, Donnenberg MS.

Infect Immun. 2007 Jun;75(6):3027-32. Epub 2007 Apr 2.

17.

Polysaccharide microarray technology for the detection of Burkholderia pseudomallei and Burkholderia mallei antibodies.

Parthasarathy N, DeShazer D, England M, Waag DM.

Diagn Microbiol Infect Dis. 2006 Nov;56(3):329-32. Epub 2006 Jun 12. Erratum in: Diagn Microbiol Infect Dis. 2008 Sep;62(1):117.

PMID:
16765554
18.

Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.

Treviño SR, Permenter AR, England MJ, Parthasarathy N, Gibbs PH, Waag DM, Chanh TC.

Infect Immun. 2006 Mar;74(3):1958-61.

19.

A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei.

Waag DM, McCluskie MJ, Zhang N, Krieg AM.

Infect Immun. 2006 Mar;74(3):1944-8.

20.

Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice.

Amemiya K, Meyers JL, Trevino SR, Chanh TC, Norris SL, Waag DM.

Vaccine. 2006 Feb 27;24(9):1413-20. Epub 2005 Sep 22.

PMID:
16213631
21.

Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice.

Ulrich RL, Amemiya K, Waag DM, Roy CJ, DeShazer D.

Vaccine. 2005 Mar 14;23(16):1986-92.

PMID:
15734072
22.

Biodefense-driven murine model of pneumonic melioidosis.

Jeddeloh JA, Fritz DL, Waag DM, Hartings JM, Andrews GP.

Infect Immun. 2003 Jan;71(1):584-7.

23.

Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol.

Waag DM, England MJ, Tammariello RF, Byrne WR, Gibbs P, Banfield CM, Pitt ML.

Vaccine. 2002 Jun 7;20(19-20):2623-34.

PMID:
12057622
24.

Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Amemiya K, Bush GV, DeShazer D, Waag DM.

Infect Immun. 2002 May;70(5):2319-25.

25.
27.

Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei).

Fritz DL, Vogel P, Brown DR, Deshazer D, Waag DM.

Vet Pathol. 2000 Nov;37(6):626-36.

PMID:
11105952
28.
29.
30.
31.

The hamster model of intraperitoneal Burkholderia mallei (glanders).

Fritz DL, Vogel P, Brown DR, Waag DM.

Vet Pathol. 1999 Jul;36(4):276-91.

PMID:
10421094
32.

Comparison of Q fever cellular and chloroform-methanol residue vaccines as skin test antigens in the sensitized guinea pig.

Elliott JJ, Ruble DL, Zaucha GM, Jaax GP, Waag DM.

Acta Virol. 1998 Jun;42(3):147-55.

PMID:
9842444
33.

Prevalence of Coxiella burnetii infections among North Dakota sheep producers.

Guo HR, Gilmore R, Waag DM, Shireley L, Freund E.

J Occup Environ Med. 1998 Nov;40(11):999-1006.

PMID:
9830608
34.

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM.

Vaccine. 1998 Jul;16(11-12):1141-8.

PMID:
9682372
37.

Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers.

Waag DM, Sandström G, England MJ, Williams JC.

FEMS Immunol Med Microbiol. 1996 Mar;13(3):205-9.

PMID:
8861030
38.

Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis.

Waag DM, McKee KT Jr, Sandstrom G, Pratt LL, Bolt CR, England MJ, Nelson GO, Williams JC.

Clin Diagn Lab Immunol. 1995 Mar;2(2):143-8.

39.

A refined guinea pig model for evaluating delayed-type hypersensitivity reactions caused by Q fever vaccines.

Ruble DL, Elliott JJ, Waag DM, Jaax GP.

Lab Anim Sci. 1994 Dec;44(6):608-12.

PMID:
7898035
40.

Evaluation of specificity of indirect enzyme-linked immunosorbent assay for diagnosis of human Q fever.

Uhaa IJ, Fishbein DB, Olson JG, Rives CC, Waag DM, Williams JC.

J Clin Microbiol. 1994 Jun;32(6):1560-5. Erratum in: J Clin Microbiol 1994 Sep;32(9):2343.

41.
42.

Cell-mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis.

Waag DM, Galloway A, Sandstrom G, Bolt CR, England MJ, Nelson GO, Williams JC.

J Clin Microbiol. 1992 Sep;30(9):2256-64.

43.

Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals.

Williams JC, Peacock MG, Waag DM, Kent G, England MJ, Nelson G, Stephenson EH.

Ann N Y Acad Sci. 1992 Jun 16;653:88-111. Review.

PMID:
1626897
44.

Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever.

Williams JC, Hoover TA, Waag DM, Banerjee-Bhatnagar N, Bolt CR, Scott GH.

Ann N Y Acad Sci. 1990;590:370-80.

PMID:
2378463
45.
46.

Poker players' pneumonia. An urban outbreak of Q fever following exposure to a parturient cat.

Langley JM, Marrie TJ, Covert A, Waag DM, Williams JC.

N Engl J Med. 1988 Aug 11;319(6):354-6. No abstract available.

PMID:
3393197
47.

Exposure to parturient cats: a risk factor for acquisition of Q fever in Maritime Canada.

Marrie TJ, Durant H, Williams JC, Mintz E, Waag DM.

J Infect Dis. 1988 Jul;158(1):101-8.

PMID:
3392409
48.
50.

Supplemental Content

Support Center